Our partners
From biotech startups to commercial partners to partners in oncology and urology, join the ever-growing community working with Photocure
Out-licensing
Asieris Meditech Co., Ltd
In July 2019, Photocure entered into a License Agreement providing Asieris Meditech Co., Ltd (Asieris) with a world-wide license to develop and commercialize Cevira® for the treatment of HPV induced cervical precancerous lesions.
In addition, in January 2021 Asieris has obtained exclusive rights from Photocure to register and commercialize Hexvix® in Mainland China and Taiwan.
This link will direct you to a site outside of PhotocureEndotherapeutics Group
In Q1 2022, Photocure entered into an exclusive distribution agreement with Endotherapeutics Group for the commercialization of Hexvix® in Australia and New Zealand.
This link will direct you to a site outside of PhotocureGenotests SpA
In August 2020, Photocure appointed Genotests SpA, a privately held company founded in 2014 specializing in genetic tests for cancer targeting cancer specialists, as the exclusive distributor for the commercialization of Hexvix® in Chile.
IGL Medical
Photocure entered into an exclusive distribution agreement with IGL Medical in June 2022 for the commercialization of Hexvix® in Israel.
This link will direct you to a site outside of PhotocureManaged Access Programs
Equity Pharmaceuticals PTY Limited
In September 2024, Photocure entered into an agreement with Equity Pharmaceuticals PTY Limited, part of Clinigen South Africa, a privately owned South African-based specialist Pharmaceutical and Medical Technology business, to initiate a Named Patient Program (NPP) enabling bladder cancer patients in South Africa to receive blue light cystoscopy (BLC®) with Hexvix®.